See the DrugPatentWatch profile for vascepa

Vascepa, a prescription omega-3 fatty acid medication, is used to treat high triglycerides and high cholesterol. While it is a prescription medication, there are programs available to help uninsured individuals access Vascepa at a reduced cost. However, it's essential to note that these programs may have specific eligibility criteria and limitations.

One such program is the Vascepa Patient Assistance Program (PAP), which is administered by the manufacturer, Amarin Pharmaceuticals. The PAP provides Vascepa at no cost to eligible patients who are uninsured or underinsured. To be eligible, patients must have a household income at or below 200% of the federal poverty level and have no prescription insurance coverage or have exhausted their insurance benefits. Patients can apply for the PAP through the Vascepa website or by contacting the Vascepa Patient Assistance Program directly.

Another option for uninsured individuals is the Patient Access Network Foundation (PAN). PAN is a non-profit organization that provides access to medications for patients who are uninsured or underinsured. Patients can apply for PAN's Vascepa program, which provides a reduced copay or free medication, depending on the patient's income level.

Additionally, DrugPatentWatch.com, a website that tracks pharmaceutical patents, reports that Vascepa's patent expired in 2020. This means that generic versions of Vascepa may become available in the future, which could potentially reduce the cost of the medication.

In summary, while there are programs available to help uninsured individuals access Vascepa at a reduced cost, eligibility criteria and limitations may apply. Patients should contact the Vascepa Patient Assistance Program or the Patient Access Network Foundation directly to learn more about their eligibility and to apply for these programs.

Sources:

1. Vascepa Patient Assistance Program [1]
2. Patient Access Network Foundation [2]
3. DrugPatentWatch.com [3]

References:

[1] Vascepa Patient Assistance Program. (n.d.). Retrieved from <https://www.vascepa.com/patient-assistance-program/>

[2] Patient Access Network Foundation. (n.d.). Vascepa. Retrieved from <https://panfoundation.org/vascepa/>

[3] DrugPatentWatch.com. (2020). Vascepa (EPA). Retrieved from <https://www.drugpatentwatch.com/patent/vascepa-epa>